Réglementation et droit · 23/12/19971 min de lecture
Prospective Grant of Exclusive License: Pharmaceutical Compositions And Methods For Treatment of Hyperproliferative Epithelial Skin Diseases and Cancer
Traduction automatique locale · Langue originale de la source
Résumé
This is notice in accordance with 35 U.S.C. Sec. 209(c)(1) and 37 CFR 404.7(a)(1)(I) that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the inventions embodied in the U.S. Patent Application SN 07/677,429 ``Pharmaceutical Compositions And Methods For Preventing Skin Tumor Formation And Causing Regression Of Existing Tumors'' filed 3/29/91 and U.S. Patent Application SN 08/ 389,845 ``Method For The Treatment Of Hyperproliferative Epithelial Skin Disease By Topical Application Of Hydroxylated Aromatic Protein * * *'' filed 2/2/95 now U.S. Patent 5,610,185 issued 3/11/97 to Nascent Pharmaceuticals, L.L.C. of San Francisco, CA. The patent rights in this invention have been assigned to the United States of America. The prospective exclusive license field of use may be limited to: Therapeutics for treatment and prevention of various hyperproliferative skin diseases in humans.